Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.

被引：2

作者：

Zhu, Viola Weijia

Bestvina, Christine M.

Lopes, Gilberto

Hamm, John Turner

Johnson, Melissa Lynne

Lammers, Philip Edward

Le, Xiuning

Marathe, Omkar

Raez, Luis E.

Rao, Suman

Sabari, Joshua K.

Scheff, Ronald J.

Tapan, Umit

Thompson, Jonathan Robert

Karachaliou, Niki

Ellers-Lenz, Barbara

Brutlach, Sabine

Smit, Egbert F.

Wu, Yi-Long

机构：

[1] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

[4] Norton Canc Inst PARENT, Louisville, KY USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Baptist Canc Ctr, Memphis, TN USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Innovat Clin Res Inst, Anaheim, CA USA

[9] Mem Healthcare Syst, Hollywood, FL USA

[10] Medstar Franklin Sq Clin Res Ctr, Baltimore, MD USA

[11] NYU Langone Clin Canc Ctr, New York, NY USA

[12] Weill Cornell Med Coll, New York, NY USA

[13] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA

[14] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[15] Merck KGaA, Global Clin Dev, Darmstadt, Germany

[16] Merck KGaA, Dept Biostat, Darmstadt, Germany

[17] Merck KGaA, Darmstadt, Germany

[18] Netherlands Canc Inst, Amsterdam, Netherlands

[19] Guangdong Prov Peoples Hosp & Guangdong Acad Med, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.TPS9136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9136

引用

下载

页数：3

共 50 条

[1] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
Dooms, C.
Nadal, E.
Raskin, J.
Demedts, I.
Mazieres, J.
Wislez, M.
Abdul, S.
Mun, T. L.
Wang, C.
Viteri, S.
Le, X.
How, S. H.
Tan, D.
Takeda, M.
Veillon, R.
Karachaliou, N.
Ellers-Lenz, B.
Smit, E.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
[2] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
Wu, Y-L.
Dooms, C.
Nadal, E.
Raskin, J.
Demedts, I.
Mazieres, J.
Wislez, M.
Abdul Shukor, S.
Tho, L. M.
Wang, C-C.
Viteri, S.
Le, X.
How, S. H.
Tan, D.
Takeda, M.
Veillon, R.
Karachaliou, N.
Ellers-Lenz, B.
Smit, E. F. F.
ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
[3] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
Smit, E. F.
Felip, E.
Karachaliou, N.
Ellers-Lenz, B.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
[4] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Liam, C. K.
Kim, T. M.
Yang, J-J.
Huang, C.
Voon, P-J.
Tho, L. M.
Zhou, Q.
Wang, J.
Hayashi, H.
Tan, D. S. W.
Danchaivijitr, P.
Nguyen, V. N.
Wong, K. H.
Yang, J. C-H.
Le, X.
Ellers-Lenz, B.
Karachaliou, N.
Ghori, V.
Berghoff, K.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
[5] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
Le, Xiuning
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jinji
Wislez, Marie
Huang, Cheng
Liam, Chong Kim
Mazieres, Julien
Lye Mun Tho
Hayashi, Hidetoshi
Nguyen Nhung
Chia, Puey Ling
De Marinis, Fillippo
Raskin, Jo
Zhou, Qinghua
Finochhiaro, Giovanna
Tan, Daniel
Brutlach, Sabine
O'Brate, Aurora
Adrian, Svenja
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Wu, Yi-Long
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[6] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
Smit, E.
Felip, E.
Karachaliou, N.
Ellers-Lenz, B.
Wu, Y. -L.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
[7] INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Yang, J. C-H.
Ellers-Lenz, B.
Straub, J.
Johne, A.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2019, 30
[8] INSIGHT 2: a Phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance
Smit, Egbert F.
Dooms, Christophe
Raskin, Jo
Nadal, Ernest
Tho, Lye M.
Le, Xiuning
Mazieres, Julien
Hin, How S.
Morise, Masahire
Zhu, Viola W.
Tan, Daniel
Holmberg, Kristina H.
Ellers-Lenz, Barbara
Adrian, Svenja
Brutlach, Sabine
Schumacher, Karl M.
Karachaliou, Niki
Wu, Yi-Long
FUTURE ONCOLOGY, 2022, 18 (09) : 1039 - 1054
[9] INSIGHT2: Tepotinib plus osimertinib in pts with EGFR-mutant NSCLC and acquired resistance to 1L osimertinib due to METamp
Morise, Masahiro
Sakai, Hiroshi
Kato, Terufumi
Tokito, Takaaki
Takeda, Masayuki
Tanaka, Hiroshi
Chikamori, Kenichi
Daga, Haruko
Kijima, Takashi
Ohashi, Kadoaki
Karachaliou, Niki
Ellers-Lenz, Barbara
Wu, Yi-Long
ANNALS OF ONCOLOGY, 2021, 32 : S309 - S309
[10] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jin-ji
Wislez, Marie
Huang, Cheng
Liam, Chong Kin
Mazieres, Julien
Tho, Ye Mun
Hayashi, Hidetoshi
Nhung Nguyen
Chia, Puey Ling
de Marinis, Filippo
Raskin, Jo
Zhou, Qinghua
Finocchiaro, Giovanna
Le, Xiuning
Tan, Daniel
O'Hara, Richard M., Jr.
Brutlach, Sabine
O'Brate, Aurora
Adrian, Svenja
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Wu, Yi-Long
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E38 - E38

← 1 2 3 4 5 →